Stock INMB INMUNE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News INmune Bio, Inc.

Equities

INMB

US45782T1051

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
11.29 USD +4.15% Intraday chart for INmune Bio, Inc. +34.89% +0.27%
04-23 Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro? for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay CI
04-08 INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GL
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AQ
INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling and Development of Novel Immunogenicity Assay
AQ
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
AQ
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
GL
Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro? for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
CI
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
GL
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
GL
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
AQ
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
CI
Transcript : INmune Bio, Inc., Q4 2023 Earnings Call, Mar 28, 2024
INmune Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
AQ
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
GL
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
GL
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
AQ
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
GL
INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro
CI
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GL
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INMB Stock
  4. News INmune Bio, Inc.